Friday, November 20, 2015 10:21:19 PM
Your main concern appears to be that MSTX is not attempting to cure Sickle Cell Disease, right? (Just trying to sort this out.) and you are talking about a test. Would that be a test to rule out the chance that a baby in utero has the genes for sickle cell disease? I understand you may be talking about amniocentesis and somehow are connecting an eventual cure to sickle cell disease. I do not see anything wrong with a desire for those and maybe there is a company or a university that is working on certain aspects of those genetic studies and and the application of that to an eventual cure. You might want to google those and you may find satisfaction in supporting those researchers who are developing a platform , moving more toward your desires.
I am much impressed with the MSTX platform and stated goals. I am impressed with the continuity and focus of research programming. It appears to me that their accomplishments well support the reduction of human suffering. (There will be a time when family members are able to share their personal experiences with this drugs function in the SICKLE CELL vascular occlusive event. ) Its a drug platform addressing vascular and blood health, specific to the traumatic occlusive event. It is not a genetic platform or a cure platform. But once again, there may be researchers who's body of work more closely matches your desires. There would be nothing wrong with your presenting your desires with the MSTX board. It is important that you, as an active investor, express your desires, directly. There is no one here who can address your concerns, whether they agree with you or not, right? I wish you all the best. I appreciate that there is nothing I can do to assist you. But good luck in your endeavor. All stated here is strictly my opinion.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM